A new retrospective study has analyzed the long-term outcomes of patients originally enrolled in CYCLOPS, in which daily oral (DO) was compared with pulse cyclophosphamide for remission induction in antineutrophil cytoplasmic antibody-associated vasculitis. On the basis of physician records—which included data on relapse, cancer incidence, bone fractures and cardiovascular morbidity—patients who were originally enrolled in the pulse arm had a higher risk of relapse than those in the DO arm, but survival rates did not differ between the two groups (P = 0.92).
ORIGINAL RESEARCH PAPER
Harper, L. et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2011-200477
Rights and permissions
About this article
Cite this article
Long-term data on cyclophosphamide regimens. Nat Rev Rheumatol 8, 62 (2012). https://doi.org/10.1038/nrrheum.2011.212
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.212